Reviewed,
UniProtKB/Swiss-Prot Q9NVS9 (PNPO_HUMAN)
Last modified
July 7, 2009.
Version 80.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Pyridoxine-5'-phosphate oxidase EC=1.4.3.5 Alternative name(s): Pyridoxamine-phosphate oxidase | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) [Complete proteome] | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 261 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP). Ref.6 |
| Catalytic activity | Pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + NH3 + H2O2. Pyridoxine 5'-phosphate + O2 = pyridoxal 5'-phosphate + H2O2. |
| Cofactor | Binds 1 FMN per subunit. |
| Pathway | |
| Subunit structure | Homodimer. Ref.6 |
| Involvement in disease | Defects in PNPO are the cause of pyridoxine-5'-phosphate oxidase deficiency (PNPO deficiency) [MIM:610090]; also known as PNPO-related neonatal epileptic encephalopathy. The main feature of neonatal epileptic encephalopathy is the onset within hours of birth of a severe seizure disorder that does not respond to anticonvulsant drugs and can be fatal. Seizures can cease with the administration of PLP, being resistant to treatment with pyridoxine,. |
| Sequence similarities | Belongs to the pyridoxamine 5'-phosphate oxidase family. |
Ontologies
| Keywords | |
|---|---|
| Biological process | Pyridoxine biosynthesis |
| Coding sequence diversity | Polymorphism |
| Disease | Disease mutation Epilepsy |
| Ligand | FMN Flavoprotein Pyridoxal phosphate |
| Molecular function | Oxidoreductase |
| PTM | Phosphoprotein |
| Technical term | 3D-structure Complete proteome Direct protein sequencing |
| Gene Ontology (GO) | |
| Biological process | oxidation reduction Inferred from electronic annotation. Source: UniProtKB-KW pyridoxine biosynthetic processInferred from electronic annotation. Source: UniProtKB-KW |
| Molecular function | FMN binding Inferred from electronic annotation. Source: InterPro pyridoxamine-phosphate oxidase activityInferred from electronic annotation. Source: EC |
| Complete GO annotation... | |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 261 | 261 | Pyridoxine-5'-phosphate oxidase | PRO_0000167783 | |||||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||||
| Nucleotide binding | 110 – 111 | 2 | FMN | ||||||||||||||||||||||||||||||||||||||
| Nucleotide binding | 174 – 175 | 2 | FMN | ||||||||||||||||||||||||||||||||||||||
| Region | 225 – 227 | 3 | Substrate binding | ||||||||||||||||||||||||||||||||||||||
Sites | |||||||||||||||||||||||||||||||||||||||||
| Binding site | 95 | 1 | FMN | ||||||||||||||||||||||||||||||||||||||
| Binding site | 98 | 1 | FMN; via amide nitrogen | ||||||||||||||||||||||||||||||||||||||
| Binding site | 100 | 1 | Substrate | ||||||||||||||||||||||||||||||||||||||
| Binding site | 117 | 1 | FMN | ||||||||||||||||||||||||||||||||||||||
| Binding site | 157 | 1 | Substrate | ||||||||||||||||||||||||||||||||||||||
| Binding site | 161 | 1 | Substrate | ||||||||||||||||||||||||||||||||||||||
| Binding site | 165 | 1 | Substrate | ||||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||||
| Modified residue | 40 | 1 | Phosphoserine Ref.4 | ||||||||||||||||||||||||||||||||||||||
| Modified residue | 165 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||||||||||||||||||
| Modified residue | 241 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||||
| Natural variant | 50 | 1 | E → K Ref.7 | VAR_029358 | |||||||||||||||||||||||||||||||||||||
| Natural variant | 116 | 1 | R → Q: dbSNP rs17679445. | VAR_029359 | |||||||||||||||||||||||||||||||||||||
| Natural variant | 229 | 1 | R → W in PNPO deficiency; strong activity decrease. | VAR_029360 | |||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||||
| Helix | 58 – 71 | 14 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 80 – 86 | 7 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 92 – 98 | 7 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 106 – 112 | 7 | |||||||||||||||||||||||||||||||||||||||
| Helix | 116 – 123 | 8 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 126 – 133 | 8 | |||||||||||||||||||||||||||||||||||||||
| Helix | 134 – 136 | 3 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 138 – 148 | 11 | |||||||||||||||||||||||||||||||||||||||
| Helix | 151 – 160 | 10 | |||||||||||||||||||||||||||||||||||||||
| Helix | 163 – 171 | 9 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 176 – 179 | 4 | |||||||||||||||||||||||||||||||||||||||
| Helix | 181 – 194 | 14 | |||||||||||||||||||||||||||||||||||||||
| Turn | 195 – 197 | 3 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 206 – 211 | 6 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 214 – 220 | 7 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 228 – 234 | 7 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 254 – 259 | 6 | |||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | Kwon O.-S. Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Brain. |
| [2] | "Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. Sugano S.Nat. Genet. 36:40-45(2004) [PubMed: 14702039] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Teratocarcinoma. |
| [3] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Lymph. |
| [4] | "Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry." Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A. Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007) [PubMed: 17287340] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40, MASS SPECTROMETRY. |
| [5] | Colinge J., Superti-Furga G., Bennett K.L. Submitted (OCT-2008) to UniProtKB Cited for: IDENTIFICATION [LARGE SCALE ANALYSIS], MASS SPECTROMETRY. |
| [6] | "Structure and properties of recombinant human pyridoxine 5'-phosphate oxidase." Musayev F.N., Di Salvo M.L., Ko T.-P., Schirch V., Safo M.K. Protein Sci. 12:1455-1463(2003) [PubMed: 12824491] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 49-161 IN COMPLEX WITH FMN AND PYRIDOXAL 5'-PHOSPHATE, PARTIAL PROTEIN SEQUENCE, SUBUNIT, ENZYME REGULATION, FUNCTION. |
| [7] | "Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase." Mills P.B., Surtees R.A.H., Champion M.P., Beesley C.E., Dalton N., Scambler P.J., Heales S.J.R., Briddon A., Scheimberg I., Hoffmann G.F., Zschocke J., Clayton P.T. Hum. Mol. Genet. 14:1077-1086(2005) [PubMed: 15772097] [Abstract] Cited for: VARIANT PNPO DEFICIENCY TRP-229, VARIANT LYS-50. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AF468030 mRNA. Translation: AAM76918.1. AK001397 mRNA. Translation: BAA91668.1. BC006525 mRNA. Translation: AAH06525.1. | |||||||||||||
| IPI | IPI00018272. | ||||||||||||
| RefSeq | NP_060599.1. | ||||||||||||
| UniGene | Hs.631742 | ||||||||||||
3D structure databases | |||||||||||||
| |||||||||||||
| DisProt | DP00168. | ||||||||||||
| ModBase | Search... | ||||||||||||
PTM databases | |||||||||||||
| PhosphoSite | Q9NVS9. | ||||||||||||
2-D gel databases | |||||||||||||
| REPRODUCTION-2DPAGE | IPI00018272. | ||||||||||||
Proteomic databases | |||||||||||||
| PeptideAtlas | Q9NVS9. | ||||||||||||
| PRIDE | Q9NVS9. | ||||||||||||
Genome annotation databases | |||||||||||||
| Ensembl | ENSG00000108439. Homo sapiens. [Contig view] | ||||||||||||
| GeneID | 55163. | ||||||||||||
| KEGG | hsa:55163. | ||||||||||||
| NMPDR | fig|9606.3.peg.13977. | ||||||||||||
| UCSC | uc002imo.1. human. | ||||||||||||
Organism-specific databases | |||||||||||||
| GeneCards | GC17P043373. | ||||||||||||
| H-InvDB | HIX0013930. | ||||||||||||
| HGNC | HGNC:30260. PNPO. | ||||||||||||
| MIM | 603287. gene. 610090. phenotype. | ||||||||||||
| Orphanet | 1934. Early infantile epileptic encephalopathy. | ||||||||||||
| PharmGKB | PA134915565. | ||||||||||||
| GenAtlas | Search... | ||||||||||||
Phylogenomic databases | |||||||||||||
| HOGENOM | Q9NVS9. | ||||||||||||
| HOVERGEN | Q9NVS9. | ||||||||||||
| OMA | Q9NVS9. FTFFTNY. | ||||||||||||
Enzyme and pathway databases | |||||||||||||
| BRENDA | 1.4.3.5. 247. | ||||||||||||
Gene expression databases | |||||||||||||
| ArrayExpress | Q9NVS9. | ||||||||||||
| Bgee | Q9NVS9. | ||||||||||||
| CleanEx | HS_PNPO. | ||||||||||||
| GermOnline | ENSG00000108439. Homo sapiens. | ||||||||||||
Family and domain databases | |||||||||||||
| InterPro | IPR011576. PNPOx_rel_FMN_bd_core. IPR000659. Pyridoxamine_oxidase. IPR019740. Pyridoxamine_oxidase_CS. IPR019576. Pyridoxamine_oxidase_dimer_C. IPR012349. Split_barrel_FMN_bd. [Graphical view] | ||||||||||||
| Gene3D | G3DSA:2.30.110.10. PNPOx_FMN_bd. 1 hit. | ||||||||||||
| PANTHER | PTHR10851. Pyridox_oxidase. 1 hit. | ||||||||||||
| Pfam | PF10590. PNPOx_C. 1 hit. PF01243. Pyridox_oxidase. 1 hit. [Graphical view] | ||||||||||||
| ProDom | PD006312. Pyridox_oxidase. 1 hit. [Graphical view] [Entries sharing at least one domain] | ||||||||||||
| TIGRFAMs | TIGR00558. pdxH. 1 hit. | ||||||||||||
| PROSITE | PS01064. PYRIDOX_OXIDASE. 1 hit. [Graphical view] | ||||||||||||
| ProtoNet | Search... | ||||||||||||
Other Resources | |||||||||||||
| DrugBank | DB00114. Pyridoxal Phosphate. | ||||||||||||
| NextBio | 58925. | ||||||||||||
| SOURCE | Search... | ||||||||||||
Entry information
| Entry name | PNPO_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q9NVS9 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation project | HPI (Human Proteome Initiative) | ||||||||
Relevant documents
| Human chromosome 17 Human chromosome 17: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PATHWAY comments Index of metabolic and biosynthesis pathways |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with


